Omega-3 Leadership KD Pharma Group is the world’s leading API producer for Omega-3 pharmaceuticals and also strong in Omega-3 nutraceuticals, formulation and encapsulation. This positions them as a strategic partner for customers seeking high-purity, scalable Omega-3 solutions, enabling joint development, custom API supply, and contract manufacturing services.

Global expansion With facilities and presence in the UK, Norway, Germany, Switzerland, and the US, the company demonstrates a global manufacturing and R&D footprint. This supports multinational clinical programs, regional regulatory navigation, and nearshore supply options for customers operating in multiple markets.

New testing lab The launch of KD LabService Omega-3 Testing Laboratory and Analytics signals an in-house quality and compliance resource. This can shorten time-to-market for customers, offer rigorous quality assurance, and enable joint testing and analytics collaborations.

Strategic partnerships Recent collaborations, including the Daiken partnership on high-concentration fish oil and algae-based Omega-3 initiatives like Alga3, indicate a momentum in sourcing innovations and alternative feedstocks. This opens avenues for co-development, supply diversification, and accessible algal omega-3 options for clients with sustainability goals.

Financial scale A revenue range of 50–100 million and substantial funding indicate a capable, growth-minded partner with investment capacity for large-scale CDMO projects, long-term contracts, and capacity expansion—appealing to customers seeking reliable, well-backed manufacturing collaborations.